Johnson & Johnson To Pay More Than $1.6 Billion To Resolve Healthcare Fraud Allegations

Monday, November 4, 2013

Tennessee will receive more than $12 million as part of a multistate and federal agreement resolving allegations pharmaceutical manufacturer Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., used deceptive marketing tactics. Specifically, the parties will pay $1.6 billion to resolve civil and criminal allegations of unlawful marketing practices to promote the sales of their atypical antipsychotic drugs, Risperdal and Invega. 

J&J and Janssen will pay in excess of $1.2 billion to the states and the federal government to resolve four qui tam, or whistleblower, lawsuits filed in the U.S. District Court for the Eastern District of Pennsylvania under the provisions of the federal False Claims Act and similar state False Claims statutes. In addition, Janssen Pharmaceuticals, Inc. will plead guilty in federal court to a criminal misdemeanor charge of misbranding Risperdal in violation of the Food, Drug, and Cosmetic Act.  As part of the criminal plea, Janssen has agreed to pay an additional $400 million in criminal fines and forfeitures.

“We applaud the cooperative work of the states and federal government to stop drug companies from illegally marketing potentially dangerous drugs to the public,” Tennessee Attorney General Bob Cooper said.  “The public needs to be able to trust those responsible for their health and well-being, and that includes drug manufacturers and those who prescribe medications.” 

J & J and Janssen allegedly promoted, marketed and introduced Risperdal and Invega into interstate commerce for uses not approved by the Food and Drug Administration and for uses that were not medically indicated.  Once the FDA approves a drug as safe and effective, a manufacturer cannot market or promote a drug for an “off-label” or other use not identified in the FDA-approved product label.  The states contend that during the period Jan. 1, 1999 through Dec. 31, 2005, the companies promoted Risperdal for off-label uses and made false and misleading statements about the safety and efficacy of Risperdal.

The states additionally allege J&J and Janssen paid illegal kickbacks to health care professionals and long-term care pharmacy providers to induce them to promote or prescribe Risperdal to children, adolescents and the elderly when there was no FDA approval for Risperdal use in these patient populations. The states further contend that from Jan. 1, 2007 through Dec. 31, 2009, the companies promoted Invega for off-label uses and made false and misleading statements about the safety and efficacy of Invega.  The manufacturers’ alleged unlawful conduct caused false and/or fraudulent claims to be submitted to or caused purchases by government funded health care programs, including the state Medicaid programs. 

As part of the global resolution, the companies will enter into a Corporate Integrity Agreement with the U.S. Department of Health and Human Services, Office of the Inspector General, which will monitor the company’s future marketing practices.

A team from the National Association of Medicaid Fraud Control Units worked with the federal government on the investigation and conducted the settlement negotiations with the pharmaceutical manufacturers on behalf of the states.  Team members included representatives from the Offices of the Attorneys General for the states of New York, Massachusetts, Ohio and California.

Chattanooga CARES Begins Syringe Exchange Program Addressing Opioid Crisis In TN

Syringe Trade and Education Program of TN is being initiated and operated by Chattanooga CARES starting Monday to tackle the underlying community health concerns created by the opioid epidemic. "The purpose behind Chattanooga CARES launching STEP TN is to reduce the spread of HIV/AIDS, viral hepatitis, and other blood borne diseases, reduce needle stick injuries to law enforcement ... (click for more)

Matters Of The Mind: A Sereies On Memory Loss Begins March 22 At CHI

CHI Memorial Center for Healthy Aging is starting a series called Matters of the Mind: A Series on Memory Loss.  The first session will be held Thursday, March 22 from 6-7 p.m. at CHI Memorial Hospital Hixson’s Professional Office Building, 2051 Hamill Road, third floor conference room, in Hixson.     The topic will be “The Dementia Umbrella: Types of Dementia.”  ... (click for more)

Volkswagen Sets Press Conference To Announce New Project; Governor Haslam To Attend

Volkswagen has called a press conference at its Chattanooga plant on Monday to announce "a new project." Governor Bill Haslam is among those set to attend. Also taking part will be Antonio Pinto, president and CEO of the Volkswagen Chattanooga plant, and Hinrich J. Woebcken, president and CEO of Volkswagen group of America. The announcement will be at 2:30 p.m. at the plant ... (click for more)

Clark D. Nolan, Accused Of Imprisoning And Assaulting Wife, Found Competent To Stand Trial

A Graysville, Tn., man who allegedly strangled, assaulted and threatened to kill his wife while holding her prisoner in their home is competent to stand trial, according to two forensic evaluators. Psychologist Robert W. Brown Jr. and forensic coordinator Todd Wiggins reported to Sequatchie County General Sessions Court that they evaluated Clark Dean Nolan on charges of aggravated ... (click for more)

Why Are Pictures Of Our President And Vice President Not Hanging At Our Federal Courthouse?

I would like to know why the pictures of our President and Vice President have not been hung in our Federal Courthouse. They have been approved by the White House. Every time I call they tell me they are on order. Tommy Fryar (click for more)

Roy Exum: The Saturday Funnies

As your dress in your best green outfit today so you can join in the Saint Patrick’s Day revelry, here’s a conversation that was overhead at an Irish pub in Killarney. Finnegan is sitting in his favorite corner, using some of the proceeds after selling his friend Michael a donkey. Suddenly Michael bolts in the door and yells, “Hey, Finnegan, that donkey you sold me went and died.' ... (click for more)